Sosa-López S, Zepeda-Romero LC, Limón-Villalpando S, Valle-Delgado E, González-Barrientos YG, Sedano-Alcaraz AJ, Sánchez-Cervantes A, Romero-González AE, García de Quevedo-Iturbide S, Vázquez-Pérez D, Gálvez-López AG, Macedo-Montero MG, Ordoñez-Cárdenas M

Language: Spanish
References: 10
Page: 235-239
PDF size: 705.83 Kb.

ABSTRACT

Introduction. Neonatal care characteristics and absence of prevention; detection and treatment programs for premature retinopathy cause it to be the main cause of infantile blindness in Mexico. The following work was done with the objective to know the distribution of treatment types used for retinopathy at the external neonatal intensive care unit in Hospital Civil de Guadalajara Fray Antonio Alcalde.
Material and Methods. We used a case descriptive study of newborn retinopathy at the ENICU in Hospital Civil de Guadalajara Fray Antonio Alcalde. Analysis took place from January 2014 to March 2016. The following variables were obtained for analysis: gender, gestational age, weight and retinopathy stages. An excel data base was used for analysis.
Results. A total of 47 premature neonates with retinopathy were included. We obtained the following data: the mayor treatment incidence was among patients weighing 800 to 1000 grams and with a gestational age ranging from 28 to 30 weeks. This series showed no gender predominance and according to diagnosis, grade III was the most common in every zone. According to the treatment applied, the most frequent was laser photocoagulation (n=30) (64%), followed by antiangiogenic treatment (n=15) (32%) and lastly, vitrectomy (n=2)(4%).
Discussion. Our case series shows similar information to the one obtained in other studies of patients requiring treatment. It is well known that treatment with laser photocoagulation has a greater predictability in the disease control, since it has been with us for long time. Antiangiogenic treatment has shown good results, and our patients have experienced a favorable evolution up to this day.

REFERENCES

1. Ramírez-Ortiz MA, Lara-Molina C, Villanueva-García D, Villa-Guillén M, Jasso- Gutiérrez L, Padilla-Sierra LC, et al. Retinopatía del Prematuro: controversias en el uso de antiangiogénicos Intraoculares. Bol Med Hosp Infant Mex. 2013; 70: 344-350.

2. Arévalo J. Fernando, et al. Retina Médica: temas selectos. 1era edición. Caracas, Venezuela. 2007. Cap. 18: 267- 300.

3. Kanski JJ. Oftalmología Clínica. 5ta edición, Barcelona España. Elsevier, 2008. Cap 14: 483-485.

4. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: preliminary report. Am J Ophthalmol. 1942; 25: 203-204

5. Campo-Gesto A, Campos-García S. Manejo de la Retinopatía de la Prematuridad. Laboratorios The Innovation. 2013; 61: 1- 28.

6. Yannuzzi LA, Guyet DR, Green WR. The Retina Atlas. Louis: Mosby; 1996. pp. 470-479.

7. Boum JH, Bohild R, Mc Elvancy NG. Screening of premature infants for retinopathy of prematurity. Pediatrics. 1997; 86: 1277-1282.

8. Todd DJ. Retinopathy of prematurity in infants less than 32 weeks gestation at birth in New South Wales in 1993-1994. Ped Child Health. 1999; 35: 355-357.

9. De la Fuente-Torres MA, Ortiz-Guzmán EV, Bustos-Zepeda M, Brechtell-Bindel M. Retinopatía del Prematuro: controversias en el uso de antiangiogénicos intraoculares. Revista del Hospital General Dr. Manuel Gea González. 2001; 4: 133-137.

10. García-Serrano JL, Ramírez-García MC, Piñar-Molina R. Enfermedad plus en la retinopatía del prematuro de gestación múltiple: Análisis de riesgo. Arch Soc Esp Oftalmo [Internet]. 2009 [citado 25 de mayo de 2016]; 84 (4): 191-198. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_ar ttext&pid=S 0365-66912009000400005